How a new period checker could stop millions from ‘suffering in silence'
A charity has launched a new period symptom checker to help women and girls understand their menstrual cycle in more depth, as one of the UK's top women's health doctors warns women are "suffering in silence" with menstrual problems.
Wellbeing of Women's period checker asks users various questions about health and reproductive symptoms and takes only four minutes to complete. At the end, it drafts a letter for women to give to their GP in order to open up discussions about their symptoms.
The charity said that many women are "putting up with" debilitating pain and heavy bleeding, with those suffering from period problems waiting an average of two years before seeking help.
In 2023, a survey of 3,000 women and girls for Wellbeing of Women found that 96% experienced period pain, with 59% describing their pain as severe. A huge majority (91%) said they experienced heavy periods, with nearly half (49%) saying their bleeding was severe.
Despite their symptoms, the survey found that women and girls are often dismissed as "just having a period", with 51% saying they felt their doctors failed to take their pain seriously.
But severe pain and heavy bleeding, as well as irregular cycles, may be a sign of conditions such as endometriosis, adenomyosis, and polycystic ovarian syndrome (PCOS).
The new tool comes after the Women and Equalities Committee of MPs published a report in December concluding that many girls are leaving school without knowing what a "normal" period looks like.
The report added that the prevalence of "medical misogyny" is leading to women living with unnecessary pain for years. The MPs suggested there is a lack of medical research, treatment options and specialists, adding that the "de-prioritisation" of gynaecological care have led to waiting lists have grown faster than any other speciality.
Professor Dame Lesley Regan, a leading gynaecologist and chairwoman of Wellbeing of Women, said: "It is shocking that women are still suffering severe period pain and heavy bleeding in silence.
"A variety of medical treatments could be offered to girls and women with these distressing conditions. We hope that our new Period Symptom Checker will encourage women to speak up and seek help for their period problems.
"It aims to promote better engagement with GPs and other community healthcare professionals by creating a letter that outlines how their symptoms are affecting their everyday lives."
Watch: "I was told I had period pain - it was endometriosis, two uteruses and cervixes"
The charity also commissioned a poll, conducted by Censuswide, that found only one in 10 women can identify all the signs of heavy menstrual bleeding.
It called for better education about menstrual health and said this is urgent to encourage women to seek treatment, whether through an appointment with their GP or community healthcare professional, or by taking better care of themselves.
Dr Michael Mulholland, honorary secretary at the Royal College of GPs (RCGP), said: "It's never easy to hear when any patient reports not feeling as though they have been listened to.
"We want all women to feel confident about turning to their GP for timely and appropriate care.
"Women's health is a key part of the RCGP curriculum that all GPs in training must demonstrate competence of before they are able to practise independently as a GP, and we will continue to support initiatives like Wellbeing of Women's Period Symptom Checker to raise awareness and challenge the normalisation of period problems."
Additional reporting by PA
Read more about women's health:
How do period-tracking apps work, and should you use them for fertility? (Yahoo Life UK, 6-min read)
'Medical misogyny' means women endure years of gynaecological pain, new report says (Sky News, 3-min read)
More than a million women keep period sick days a secret (Yahoo Life UK, 6-min read)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
a day ago
- Forbes
Why Women's Health Research Still Lags Behind
Woman chemist testing for gender differences. The gender gap in healthcare isn't just a question of equity—it's a question of evidence. For too long, women have been excluded from clinical trials, overlooked in preclinical research, and underserved by healthcare systems. The consequences are both deeply personal and widely systemic: Women are more likely to be misdiagnosed, experience adverse drug reactions, and face delays in care. 'It's like death by a thousand paper cuts,' said Alisa Wilson, managing director at Accenture, in a recent interview. 'We're tackling this problem piecemeal, when what's needed is a holistic overhaul across the entire healthcare ecosystem.' New research from Accenture and Springboard Enterprises, 2025 State of Women's Health, sheds light on just how pervasive these gaps are—and what it will take to close them. Bias starts early and compounds over time. Preclinical research—the scientific foundation for nearly all therapies—is still dominated by male models. Animal studies, cell lines, and early-phase drug testing frequently rely on male subjects, based on the outdated assumption that male data is 'universal.' The result? Research hypotheses, safety profiles, and drug mechanisms are skewed from the start. Source: Accenture and Springboard 2025 State of Women's Health That bias continues into clinical trials. Even when women are included, they are often underrepresented or excluded from subgroup analyses. Women made up only 29% of heart attack clinical trial participants, even though heart disease is the number one killer of women globally, according to Accenture's analysis of data from 2020 to 2024. Women also represent just 60% of autoimmune trial participants, even though they make up about 80% of people with autoimmune conditions. 'There's a clear lack of sex-specific data,' said Miranda Ewald, director of programs at Springboard. 'When women are included in research, their outcomes are often not analyzed separately. That makes it impossible to understand how diseases or treatments affect them differently.' Lack of sex-specific dosing, unequal access to optimal treatments and unique challenges to ... More medication contribute to women's poorer health outcomes Even before a clinical trial is an option, women face significant hurdles in getting a diagnosis. On average, it takes up to 7 years to be diagnosed with conditions like polycystic ovarian syndrome (PCOS) or endometriosis. These delays are often dismissed as stress, aging, or psychosomatic symptoms. Despite biological differences, drug dosing rarely accounts for sex. Amani Bright, senior program manager at Springboard, emphasizes the importance of empathy in solving this problem. 'We need decision-makers—funders, policymakers, and healthcare systems—to understand how long and frustrating the patient journey is until they are diagnosed and treated correctly. Women are being left behind because their symptoms don't fit the outdated mold.' That frustration is not limited to patients. Healthcare innovators are also encountering barriers. 'Even with strong scientific validation, women's health startups still face real hurdles—like undefined regulatory pathways and unclear reimbursement models,' said Alice Zheng, partner at Foreground Capital. 'That slows everything down.' Despite these barriers, a new wave of innovators is reimagining how healthcare can better serve women. Companies are working to correct historical research bias by designing more inclusive clinical trials, often in partnership with patient advocacy groups and underrepresented communities. They're also thinking creatively about data collection. 'We're seeing startups use virtual consent tools and culturally sensitive materials to boost trial participation,' said Bright. 'And they're considering real-world factors like language, caregiving responsibilities, and transportation needs.' But to truly accelerate progress, innovators need more support from the healthcare establishment. 'When we worked with a major life sciences client, it took two years just to integrate sex-based thinking into their R&D pipeline,' said Wilson. 'They had never considered sex differences at the discovery stage. That's how deeply ingrained the male-default model is.' Emerging technologies, such as artificial intelligence (AI) and machine learning, offer promise in shortening the research-to-treatment gap. 'We saw how fast COVID vaccines came to market when urgency and collaboration aligned,' said Wilson. 'AI can do the same for women's health if we commit to using high-quality, inclusive data.' However, there is a caveat here as well. AI models trained on biased datasets will only perpetuate the problem. 'To leverage AI effectively, we need to ensure that data is disaggregated by sex, race, and age,' said Wilson. 'Only then can we track adverse events accurately, tailor dosage by gender, and improve safety and efficacy for all patients.' Part of the problem, all interviewees agree, is definitional. When many people hear 'women's health,' they think of reproductive health—fertility, contraception, and menopause. Those areas deserve investment, but they are just one part of a much larger picture. 'The market opportunity is not just the uterus,' said Bright. 'Women's health includes cardiovascular, autoimmune, mental health, and cognitive aging—all areas where women are differently or disproportionately impacted.' Zheng echoed this: 'If we think women's health only means OB-GYN, we're missing the big picture. Breast cancer, for example, is often called a 'solved' disease—but for women with dense breast tissue, early screening is still inadequate.' Fixing the gender gap in medicine requires systemic change. That includes: Most importantly, it requires the healthcare system to see women not as a special case, but as a default patient. The women's health gap is not a niche issue—it's a symptom of centuries of systemic neglect that continues to hinder progress in women's health innovation. When women are misdiagnosed, overlooked, or excluded from research, the entire healthcare system suffers. 'We don't need another pilot program,' said Wilson. 'We need full-scale transformation—led by research, powered by investment, and centered on the real-life experiences of women.' Advancing women's health research and innovation starts with closing the data gap—and ultimately, closing the outcomes gap.
Medscape
2 days ago
- Medscape
Hyperinsulinemia Linked to Abnormal Uterine Bleeding
Hyperinsulinemia appears to have an early association with common causes of abnormal uterine bleeding (AUB), particularly in women with obesity, a preliminary study in Menopause found. Although preliminary, the study data suggested the opportunity for future research on potential relationships between cardiovascular disease risk factors and gynecologic disease. 'Many studies and organizational bodies have examined and asserted a relationship between polycystic ovarian syndrome (PCOS) and elevated insulin levels,' wrote investigators led by Andrea C. Salcedo, DO, MPH, of the Department of Obstetrics and Gynecology at Loma Linda University in Loma Linda, California. They noted that AUB is the most common reason for benign gynecologic consultation in the United States. Andrea C. Salcedo, DO, MPH 'After over 15 years of clinical practice , I started realizing there were several patterns in women who presented with irregular or heavy periods. Many were self-referred or sent by their primary care providers to see me to evaluate for female hormone problems,' Salcedo told Medscape Medical News . 'The majority were not in perimenopause, but they had similar risk factors for cardiovascular disease, such as obesity, hypertension, and migraine headaches.' Salcedo began to wonder whether healthcare providers are recognizing abnormal periods in reproductive age as a cardiovascular risk and using them to educate women on prevention rather than solely treating them medically or surgically. 'I believe that the theory of the uterus as an 'end organ' that receives inflammation in the same way as the heart and kidneys do in cardiovascular disease helps explain to the patient the reasons for heavy or irregular periods.' The study findings came as no surprise to her: 'They confirmed the patterns I was seeing clinically.' Hyperinsulinemia is associated with smooth blood vessel inflammation in the peripheral circulation. 'What is often under-recognized is that the uterus is made of these same blood vessels.' When the uterus is on the receiving end of inflammation, the blood vessels are damaged and do not function appropriately. The result can be uterine fibroids or heavy periods. The gynecologic expression of this inflammation can vary from person to person, she added. The Study This exploratory cross-sectional analysis of the association between hyperinsulinemia and biomarkers of metabolic syndrome in reproductive-aged women with AUB was designed to motivate future hypothesis-driven research. It was conducted from June 2019 to August 2023 at a single institution's outpatient gynecology clinics. A total of 205 premenopausal women aged 18-54 years were enrolled, including 116 with AUB and 89 control individuals with normal menstrual cycles. Approximately 40% in each group were identified as Hispanic. Participants underwent assessment for fasting insulin and additional markers of metabolic syndrome, including body mass index (BMI), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and waist-to-hip ratio. Among the findings: • Hyperinsulinemia, the main effect of interest, was a significant predictor of AUB, affecting 44.0% of the AUB group vs 33.7% of the control group, with an odds ratio of 3.0 (95% CI, 1.372-6.832; P = .0085). • Hypertension, LDL, HDL, smoking, migraines, and polyps or fibroids were all significantly associated with AUB and identified as confounders. Chronic hypertension was identified in 26% of the AUB group vs 12% of the control group. • Interestingly, including BMI in the model diminished the significance of hyperinsulinemia, suggesting overlapping or mediating pathways, the authors said. • Among metabolic markers, LDL levels were similar between groups, while HDL levels were lower in women with AUB (54.0 vs 60.0 mg/dL). • There was a nonsignificant intergroup difference in triglycerides (82.0 vs 73.5 mg/dL) and total cholesterol levels (169.0 vs 172.5 mg/dL). • Migraines were more prevalent in the AUB group (31.0% vs 11.2%), as were polyps or fibroids (45.7% vs 9.6%). Commenting on the study but not involved in it, Maureen Whelihan, MD, a gynecologist at the Center for Sexual Health and Education and Elite GYN Care of the Palm Beaches in Greenacres, Florida, called the study an interesting one, 'suggesting that before we see the effects of PCOS, a diagnosis of hyperinsulinemia can be made and managed and that hyperinsulinemia has a direct effect on microinflammatory injury to the uterus.' Maureen Whelihan, MD In her practice, women with insulin resistance and PCOS have major infertility issues. 'About 85% are obese and have lipid disorders. While this study indicates we can make a diagnosis earlier by evaluating fasting insulin, the question is, 'then what?'' she said. The ultimate remedy is diet and lifestyle modification. 'The minute patients understand they must eliminate starch and sugar to lower insulin levels and move their body a little, we lose them,' she said. 'They want a quick fix and nothing that requires them to make difficult decisions and drastic modifications. This is the hard part! We can teach them the pathophysiology all day, but they have to commit to a permanent change in the way they approach diet and exercise.' While the study findings are exploratory and preliminary, Salcedo said, they suggest that abnormal periods may have predictive value. 'In many cases, elevated fasting insulin levels, above 10 µU/mL, could be an early sign of cardiovascular and diabetes disease risk.' In this study, elevated insulin levels were associated with AUB, particularly among those with obesity. 'Therefore, when a patient sees her healthcare provider for irregular periods, it could be an excellent opportunity to discuss the known association of menstrual problems with [cardiovascular] risk factors.' Larger, longitudinal studies are needed, however, to confirm the causal mechanisms, Salcedo said.
Medscape
3 days ago
- Medscape
Continuing Metformin Reduces PCOS Pregnancy Risks
Continuing metformin throughout the first trimester in women with polycystic ovary syndrome (PCOS) showed the potential to reduce miscarriage risk (odds ratio [OR], 0.64) and increase clinical pregnancy rates (OR, 1.57) compared with placebo. A meta-analysis of 12 randomized controlled trials involving 1708 women suggested that stopping metformin at pregnancy confirmation might be less beneficial than continuation through the first trimester. METHODOLOGY: Researchers conducted a systematic review and meta-analysis of randomized controlled trials evaluating metformin started preconception and continued at least until positive pregnancy test compared with placebo or no treatment in women with PCOS. The analysis included 12 trustworthy studies with 1708 participants, with trials conducted across 14 countries spanning five continents, all graded as low to moderate quality evidence. The primary outcome measure focused on miscarriage rate, defined as pregnancy loss prior to 20 completed weeks of gestation, while secondary outcomes included clinical pregnancy and live birth rates. Investigators performed indirect comparisons between treatment groups using the Bucher technique to evaluate clinical pregnancy, miscarriage, and live birth rates for metformin treatment continued throughout first trimester vs stopped at a positive pregnancy test. TAKEAWAY: Women receiving preconception metformin continued throughout the first trimester had higher clinical pregnancy rates (OR, 1.57; 95% CI, 1.11-2.23), potential reduction in miscarriage (OR, 0.64; 95% CI, 0.32-1.25), and possible increase in live birth (OR, 1.24; 95% CI, 0.59-2.61) compared with placebo or no treatment. Participants who stopped metformin once pregnant showed an increased clinical pregnancy rate (OR, 1.35; 95% CI, 1.01-1.80) but suggested higher miscarriage risk (OR, 1.46; 95% CI, 0.73-2.90) compared with placebo or no treatment. Indirect comparisons consistently favored continuing metformin through first trimester vs stopping at pregnancy confirmation for clinical pregnancy (OR, 1.16; 95% CI, 0.74-1.83), miscarriage (OR, 0.44; 95% CI, 0.17-1.16), and live birth (OR, 1.14; 95% CI, 0.41-3.13). IN PRACTICE: 'Women with PCOS have been shown to have a fivefold increased risk per year of developing insulin resistance and subsequent type 2 diabetes. Insulin resistance has been shown to be independently associated with a higher risk of miscarriage. Metformin acts by decreasing gluconeogenesis, lipogenesis and enhancing glucose uptake, all of which in turn reduce insulin resistance,' wrote the authors of the study. SOURCE: The study was led by James Cheshire, PhD, Birmingham Women's and Children's NHS Foundation Trust in Birmingham, England. It was published online in American Journal of Obstetrics and Gynecology . LIMITATIONS: According to the authors, the main limitation was the inherent heterogeneous nature of the study population and the overall low quality of evidence. Women with PCOS have different phenotypes and varying degrees of hyperandrogenism and insulin resistance, which could not be accounted for in the analyses. Additionally, many studies did not subdivide pregnancy outcome data by body mass index (BMI), preventing meaningful analyses in BMI subgroups. The limited outcome data in spontaneously conceiving populations (only 30 women from two studies) make it difficult to extrapolate findings to this group. DISCLOSURES: The authors reported having no conflicts of interest. The study received no external funding.
